MedTrace Logo

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

NCT06857955 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2026-04-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

Conditions

Interventions

OTHER

Saline

0.9% sodium chloride saline solution

DRUG

QCZ484

Solution of Injection

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2027-01-29
Completion
2028-04-05
FDA Drug
Yes

Countries

  • United States
  • Japan
  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06857955 on ClinicalTrials.gov